Why Younger People Are Getting Cancer and What We Can Do About It | Future of Health Summit 2024

Rising Incidence of Early-Onset Cancer:

• A 24-million-person study covering 2000–2020 found 17 of 34 major cancer types are increasing significantly in Millennials and Gen X compared to Baby Boomers, with some rates 2–3 times higher.
• This trend contradicts historical patterns, as some cancers rising in younger generations (e.g., colorectal, breast) are simultaneously declining in populations over 65.
• Colorectal cancer is identified as a "canary in the coal mine," prompting the American Cancer Society and US Preventive Services Task Force to lower the recommended screening age from 50 to 45.
• Screening rates remain critically low even for current guidelines; in the 45–49 age group, only ~20% undergo screening, and fewer than half of eligible older adults receive colonoscopies.

Identified and Potential Risk Factors:

• While obesity is a driver, only 10 of the 17 rising cancer types are linked to obesity, suggesting additional, unidentified environmental or lifestyle drivers.
• Potential contributing factors under investigation include ultra-processed foods, microplastics, alcohol consumption, and sedentary behaviors.
• Genetic factors are emerging as critical; a survivor case study revealed a low-risk gene mutation in a young breast cancer patient, leading to testing of extended family members.
• Disparities are stark: Black women have a 50% higher chance of dying from breast cancer than White women, and this disparity doubles for women under 40.

Screening Limitations and Innovation Needs:

• Current screening guidelines do not cover the younger population, and broad application of colonoscopy or mammography to this group yields low diagnostic value due to low baseline risk.
• Capacity for gold-standard colonoscopies is reaching limits, with wait times of 3–9 months in some US regions, necessitating alternative modalities.
• Liquid biopsy (blood-based) tests, such as Gardent Health's FDA-approved colorectal test, offer a scalable alternative to reduce the "ick factor" and logistical barriers of invasive procedures.
• Current liquid biopsy technology is highly effective at detecting established cancer but has low sensitivity for detecting pre-cancerous advanced adenomas.

Survivorship and Long-Term Care Challenges:

• A "tsunami" of young cancer survivors is anticipated, facing unique life-stage challenges including fertility preservation, sexual health, financial instability, and the risk of second primary cancers.
• Supportive care is severely underutilized: 80% of oncologists provide it, but only 26% of patients receive it, highlighting a gap in patient education and systemic integration.
• Young survivors (e.g., age 34) often face a lack of peer support and insurance coverage for long-term monitoring, as the system is optimized for the 65+ demographic.

Healthcare System and Provider Gaps:

• Primary care physicians often lack awareness of early-onset cancer trends, leading to missed diagnoses when young patients present with symptoms.
• Programs like Project ECHO and "dyad" models (e.g., Access Hope) are being deployed to connect community providers with academic centers, allowing local patients access to specialized expertise without travel.
• Narrow insurance networks and competitive divides between community and academic centers hinder the seamless flow of patients to high-complexity care and clinical trials.
• Clinical trial enrollment is disproportionately low in community settings (<2%) compared to academic centers (5–7%), limiting data diversity and access to new therapies.

Policy, Funding, and Guideline Barriers:

• The US Preventive Services Task Force (USPSTF) operates on a 5–7 year review cycle with underfunding, causing a lag between scientific innovation and guideline updates.
• Current guidelines may be over-generalized; for example, PSA testing guidelines were broadened, yet the test is highly effective for Black men who die at 100% higher rates from prostate cancer.
• Panelists warn that potential NIH funding cuts could delay the multi-decade timelines required to solve early-onset cancer causation.
• There is a call for "living" guidelines and faster regulatory pathways to integrate new preventive measures and biomarkers into standard care.

Treatment Pipeline and Future Outlook:

• Immunotherapy, cell therapies (CAR-T, NK cells), and targeted genetic treatments are progressing to address aggressive tumors common in young patients.
• Precision medicine approaches aim to combine early detection with short-duration, immune-harnessing treatments to improve long-term survival for young survivors.
• Researchers emphasize the need to study pediatric regimens in young adults (e.g., lymphoma), which have shown superior outcomes compared to standard adult protocols.
• A consensus exists that solving this crisis requires a multi-disciplinary ecosystem integrating payers, researchers, clinicians, and community advocates to address cost, false positives, and equitable access.